Use of transient evoked otoacoustic emissions to detect and monitor cochlear damage caused by platinum-containing drugs

British Journal of Audiology

Volumn 32, Issue 5, 1998, Pages 305-316

  Yardley, Mark P J ^a   Davies, Catherine M ^a   Stevens, John C ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Cisplatin; Otoacoustic toxicity; Ototoxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; COCHLEA INJURY; COMPARATIVE STUDY; EVOKED OTOACOUSTIC EMISSION; FEMALE; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; LUNG CANCER; MALE; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; TYMPANOMETRY; UROGENITAL TRACT CANCER; VOMITING;

EID: 0031739233     PISSN: 03005364     EISSN: None     Source Type: Journal    
DOI: 10.3109/03005364000000082     Document Type: Article

References (37)

1. Anderson SD. Some ECMR properties in relation to other signals from the auditory periphery. Hear Res 1980; 2: 273-96.
2. Anderson SD, Kemp DT. The evoked cochlear mechanical response in laboratory primates. A preliminary report. Arch Otorhinolaryngol 1979; 224: 47-54.
3. Association of the British Pharmaceutical Industry. Data sheet compendium 1994-95. Datapharm Publications Ltd, London, 1994.
4. Black FO, Myers EN, Schramm VL, Johnson J, Sigler B, Thearle PB, Burns DS. Cisplatinum vestibular ototoxicity: preliminary report. Laryngoscope 1982; 92: 1363-8.
5. Blakley BW, Gupta AK, Myers SF, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994; 120: 541-6.
6. British Society of Audiology. Recommended procedures for pure-tone audiometry using a manually operated instrument. Br J Audiol 1981; 15: 213-6.
7. British Society of Audiology. Recommended procedure for pure-tone bone-conduction audiometry without masking using a manually operated instrument. Br J Audiol 1985; 19: 281-2.
8. British Society of Audiology. Recommendations for masking in pure tone threshold audiometry. Br J Audiol 1986; 20: 307-14.
9. Brimmett RE, Morrison RB. The incidence of aminoglycoside antibiotic induced hearing loss. Arch Otolaryngol Head Neck Surg 1990; 116: 406-410.
10. Chapman P. Rapid onset hearing loss after cisplatin therapy: case reports and a literature review. J Laryngol Otol 1982; 96: 159-62.
11. Evans WE, Yee GC, Crom WR, Pratt CB, Green AA. Clinical pharmacology of bleomycin and cisplatin. Head and Neck Surg 1981; 4: 98-110.
12. Fausti SA, Schechter MA, Rappaport BZ, Frey RH, Mass RE. Early detection of cisplatin ototoxicity selected case reports. Cancer 1984; 53: 224-31.
13. Fleischman RW, Standnicki SW, Ethieu MF, Schaeppi U. Ototoxicity of cis-dichlorodiamine platinum (II)in the guinea pig. Toxicol Appl Pharmacol 1975; 33: 320-32.
14. Gratton MA. The interaction of cisplatin and noise on the peripheral auditory system. Hear Res 1990; 50: 211-24.
15. Hayes, DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372-81.
16. Helson L, Okonkwo E, Anton L, Cvitkovic F. Cis-platinum ototoxicity. Clin Toxicol 1978; 13: 469-78.
17. Johnsen NJ, Elberling C. Evoked acoustic emissions from the human ear. I Equipment and response parameters. Scand Audiol 1982; 11: 3-12.
18. Kemp DT. Stimulated acoustic emissions from within the human Auditory system. J Acoust Soc Am 1978; 64: 1386-91.
19. Komune S. Potentiating effects of cisplatin and ethacrynic acid in ototoxicity. Arch Otolaryngol 1981; 101: 66-74.
20. Lonsbury-Martin BL, Martin GK, McCoy MJ, Whitehead ML. New approaches to the evaluation of the auditory system and a current analysis of otoacoustic emissions. Otolaryngol Head Neck Surg 1995; 112: 50-63.
21. McFadden D, Plattsmier HS, Pasanen EG. Aspirin-induced hearing loss as a model of sensorineural hearing loss. Hear Res 1984; 16: 251-60.
22. Meyerhoff WL, Maale GE, Yellin W, Roland PS. Audiologic threshold monitoring of patients receiving ototoxic drugs. Ann Otol Rhinol Laryngol 1989; 98: 950-4.
23. Norton SJ. Applications of transient evoked otoacoustic emissions to paediatric populations. Ear Hear 1993; 14: 64-73.
24. Ozols RF, Deisseroth AB, Javadpour N, Barlock A, Messerschmidt GL, Young RG. Treatment of poor prognosis non-seminomatous testicular cancer with a 'high-dose' platinum combination chemotherapy regimen. Cancer 1993; 51: 1803-7.
25. Parti R, Wolf W. Quantitative subcellular distribution of platinum in renal tissues following IV bolus and IV infusion of cisplatin. Chemother Pharmacol 1990; 26: 188-192.
26. Plinkert PK, Krober S. Fruherkennung einer Cisplatin-Ototoxizitat durch evozierte otoakustische Emissionen. Laryngo-Rhino-Otologie 1991; 70: 457-62.
27. Pollera C. Very high dose cisplatin-induced ototoxicity: a preliminary report on early and long term effects. Cancer Chemother Pharmacol 1988; 21: 61-4.
28. Rosenburg B, Van Camp L, Krigas T. Inhibition of cell division in E. coli by electrolysis produced from a platinum electrode. Nature 1965; 205: 698-99.
29. Schaefer SD, Wright CG, Post JD, Frenkel EP. Cisplatinum vestibular toxicity. Cancer 1981; 47: 857-9.
30. Schweitzer V, Rarey V, Dolon D, Abrams G, Litterst C, Sheridan C. Ototoxicity of cisplatin versus platinum analogues CBDCA (Jm-8) and CHIP (JM-9). Otolaryngology Head Neck Surg 1986; 94: 458-70.
31. Schweitzer VG. Cisplatin-induced ototoxicity: effect of pigmentation and inhibitory agents. Laryngoscope 1993; (Suppl.) 59.
32. Strauss M, Towfighi J, Lord S, Lipton A, Harvey HA, Brown B. Cisplatin ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope 1983; 93: 1554-9.
33. Tange RA, Dreschler WA, Van Der Hulst RJAM. The importance of high tone audiometry in monitoring for ototoxicity. Arch Otorhinolaryngol 1985; 242: 77-81.
34. Wake M, Takeno S, Ibrahim D, Harrison R, Mount R. Carboplatin ototoxicity: an animal model. J Laryngol Otol 1993; 107: 585-9.
35. Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. Ototoxicity due to cis-diamminedi-chloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 1991; 12: 91-102.
36. Zorowka PG. Otoacoustic emissions: a new method to diagnose hearing impairment in children. Eur J Pediatr 1993; 152: 626-34.
37. Zorowka PG, Schmitt HJ, Gutjahr P. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatin therapy. Int J Pediatr Otorhinolaryngol 1993; 25: 73-80.